MedPath

INmune Bio Plans FDA Submission for CORDStrom in Rare Skin Disease RDEB

• INmune Bio announces plans to submit Biologics License Application (BLA) to FDA for CORDStrom following successful Type C meeting.

• The company will pursue marketing authorization in both US and European markets based on positive MissionEB clinical trial results in pediatric RDEB patients.

• Double-blind, randomized, placebo-controlled MissionEB study demonstrates favorable benefit-risk profile for CORDStrom as a disease-modifying therapy.

INmune Bio has taken a significant step forward in its mission to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB), announcing plans to submit regulatory applications following a productive Type C meeting with the U.S. Food and Drug Administration (FDA). The company intends to file a Biologics License Application (BLA) in the United States and corresponding Marketing Authorization Applications (MAA) in the United Kingdom and European Union.
The regulatory submissions will be supported by data from the company's MissionEB clinical trial, which evaluated CORDStrom as a potential disease-modifying therapy for pediatric patients suffering from RDEB. This rare genetic condition causes severe skin fragility and blistering, significantly impacting patients' quality of life from an early age.

Clinical Trial Results Support Regulatory Filing

The MissionEB study, designed as a double-blind, randomized, placebo-controlled trial, has yielded promising results that demonstrate a favorable benefit-risk profile for CORDStrom. This rigorous trial design is particularly noteworthy in the context of rare disease research, where controlled studies can be challenging to conduct due to small patient populations.

Strategic Regulatory Approach

INmune Bio's decision to pursue simultaneous regulatory approvals in multiple major markets reflects a comprehensive strategy to make CORDStrom available to RDEB patients globally. The Type C meeting with the FDA represents a critical milestone in the development program, providing the company with regulatory clarity and confidence to proceed with submission plans.

Addressing an Unmet Medical Need

RDEB represents a significant unmet medical need, with limited therapeutic options currently available for patients. CORDStrom's development as a disease-modifying therapy could potentially offer new hope to pediatric patients and their families who currently face limited treatment options for managing this devastating condition.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Biotest Submits Fibrinogen Biologics License Application to FDA

Biotest has submitted a Biologics License Application (BLA) to the FDA for its Fibrinogen product, addressing acquired fibrinogen deficiency.
The application includes treatment and prophylaxis of acute bleeding episodes in patients with congenital fibrinogen deficiency, expanding its potential use.

EMA to Review Ibrutinib for Frontline Mantle Cell Lymphoma in Transplant-Eligible Patients

Johnson & Johnson seeks EMA approval for ibrutinib plus R-CHOP for untreated MCL patients eligible for autologous stem cell transplant.
The application is based on the Phase 3 TRIANGLE study, which showed improved efficacy with ibrutinib-based regimens.

Blenrep Combination Therapy Gains Regulatory Traction for Multiple Myeloma

The NMPA of China has accepted for review GSK's NDA for Blenrep (belantamab mafodotin) combined with bortezomib and dexamethasone (BVd) for relapsed or refractory multiple myeloma.
This regulatory filing is supported by the DREAMM-7 phase III trial, demonstrating statistically significant improvements in overall survival compared to daratumumab plus bortezomib and dexamethasone (DVd).

Johnson & Johnson Seeks FDA Approval for Tremfya to Treat Pediatric Psoriasis and Arthritis

Johnson & Johnson has submitted sBLAs to the FDA for Tremfya (guselkumab) to treat moderate-to-severe plaque psoriasis in children aged 6 and older.
The submission also seeks approval for Tremfya to treat active juvenile psoriatic arthritis in children aged 5 and older.

Johnson & Johnson Seeks FDA Approval for Subcutaneous TREMFYA® in Ulcerative Colitis

Johnson & Johnson has submitted an sBLA to the FDA for a subcutaneous induction regimen of TREMFYA® (guselkumab) for treating moderately to severely active ulcerative colitis.
The submission is based on the Phase 3 ASTRO study, which met its primary endpoint of clinical remission at Week 12 using a 400 mg subcutaneous induction dose.

Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya in Ulcerative Colitis

Johnson & Johnson has submitted an sBLA to the FDA for a subcutaneous induction regimen of Tremfya (guselkumab) for treating moderately to severely active ulcerative colitis.
The submission is backed by Phase 3 ASTRO study data, which demonstrated clinical remission at Week 12 and met all secondary endpoints in adult UC patients.

FDA Accepts Abeona's BLA Resubmission for Pz-Cel in Recessive Dystrophic Epidermolysis Bullosa

The FDA has accepted Abeona Therapeutics' resubmitted Biologics License Application (BLA) for pz-cel, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).
The FDA set a PDUFA target action date of April 29, 2025, for the decision on pz-cel, an autologous, cell-based gene therapy.

J&J Seeks Approval for Daratumumab in High-Risk Smoldering Multiple Myeloma

Johnson & Johnson has submitted applications to the FDA and EMA for daratumumab to treat high-risk smoldering multiple myeloma.
The submissions are based on Phase 3 AQUILA study data, evaluating daratumumab as a monotherapy in this patient population.

SystImmune's BL-M17D1 Antibody-Drug Conjugate Receives FDA IND Clearance for Advanced Solid Tumors

SystImmune's BL-M17D1, an antibody-drug conjugate (ADC) with innovative linker and payload technology, has received FDA IND clearance for a Phase 1 clinical trial.
The Phase 1 trial, BL‑M17D1-ST-101, will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of BL-M17D1 in advanced or metastatic solid tumors.

BlueRock Therapeutics' OpCT-001 Receives FDA Clearance for Phase I/IIa Trial in Primary Photoreceptor Diseases

BlueRock Therapeutics received FDA clearance for its IND application for OpCT-001, an iPSC-derived cell therapy targeting primary photoreceptor diseases.
The Phase I/IIa trial will assess the safety, tolerability, and efficacy of OpCT-001 in restoring vision for individuals with these conditions.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy